SELLAS Life Sciences Group stock analysis
SELLAS Life Sciences Group (RXK3) Stock Price & Analysis
RXK3 Stock Chart & Stats
- Day’s Range
- EUR 6.88 - EUR 18.65
- 52-Week Range
- EUR 1.20 - EUR 18.65
- Previous Close
- EUR 7.02
- Volume
- N/A
- Average Volume (3M)
- 987
- Market Cap
- EUR 3.55B
- Enterprise Value
- EUR 2.36B
- Total Cash (Recent Filing)
- EUR 134.71M
- Total Debt (Recent Filing)
- EUR 599.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.44
- Next Earnings
- Mar 25, 2027 (Est.)
- EPS Estimate
- -0.05
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Phase 3 REGAL Validation And Regulatory Path
The positive Phase 3 result materially strengthens GPS’s clinical credibility, with a statistically significant survival benefit and no new safety signals. Planned FDA engagement and BLA preparation create a defined regulatory path that could move the lead program toward commercialization.
Multiple Oncology Immunotherapy Programs
A pipeline spanning GPS and NPS gives SELLAS more than one potential clinical value driver and applies its immunotherapy approach across different cancer settings. This diversification can support longer-term strategic flexibility if individual indications develop unevenly.
Low Leverage And Stronger Equity Capitalization
Minimal debt reduces refinancing pressure and fixed financial obligations, while the improvement in equity capitalization strengthens solvency relative to prior periods. This gives SELLAS more balance-sheet flexibility to fund clinical and regulatory work than a highly leveraged structure would.
Bears Say
Pre-revenue Business Model
SELLAS has no established commercial revenue base to absorb research, development, and corporate costs. Until a candidate is approved and launched, operating performance remains dependent on clinical progress and external capital rather than recurring product sales.
Persistent Cash Burn And Funding Needs
Continued negative operating and free cash flow means SELLAS must keep financing operations while advancing its programs. Persistent cash consumption can constrain strategic choices and require additional capital before potential product revenue becomes available.
Dependence On Equity Financing
The company’s large equity offering highlights ongoing reliance on capital markets to support development before commercialization. Issuing additional shares can dilute existing ownership and leaves future funding capacity exposed to the need for repeated financing.
SELLAS Life Sciences Group News
Why SELLAS Life Sciences Stock Is Skyrocketing Over 200% Today — and What This Analyst Sees Next
SELLAS Life Sciences (NASDAQ:SLS) stock is skyrocketing more than 200% on Tuesday after the cancer drug developer announced positive results from its late-stage leukemia trial. The company’s experimental cancer vaccine,
RXK3 FAQ
What was SELLAS Life Sciences Group’s price range in the past 12 months?
What is SELLAS Life Sciences Group’s market cap?
When is SELLAS Life Sciences Group’s upcoming earnings report date?
How were SELLAS Life Sciences Group’s earnings last quarter?
Is SELLAS Life Sciences Group overvalued?
Does SELLAS Life Sciences Group pay dividends?
What is SELLAS Life Sciences Group’s EPS estimate?
How many shares outstanding does SELLAS Life Sciences Group have?
What happened to SELLAS Life Sciences Group’s price movement after its last earnings report?
Which hedge fund is a major shareholder of SELLAS Life Sciences Group?
What is the TipRanks Smart Score and how is it calculated?
SELLAS Life Sciences Group Stock Smart Score
Company Description
SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Angelos Stergiou
- Employees
- 13
- Website
- www.sellaslifesciences.com
- Address
- 7 Times Square, New York, NY, 10036, US
SELLAS Life Sciences Group (RXK3) Earnings & Revenues
RXK3 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 3 | 3 |
| Technical Analysis | 3 | 3 | 3 |
| Moving Averages | 12 | 0 | 0 |














